Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AFM24 in Combination With Atezolizumab in Patients With Selected Advanced/Metastatic EGFR-expressing Cancers

X
Trial Profile

A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AFM24 in Combination With Atezolizumab in Patients With Selected Advanced/Metastatic EGFR-expressing Cancers

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AFM 24 (Primary) ; Atezolizumab (Primary)
  • Indications Adenocarcinoma; Biliary cancer; Gastric cancer; Liver cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms AFM24-102
  • Sponsors Affimed Therapeutics
  • Most Recent Events

    • 12 Jun 2024 According to Affimed Therapeutics media release, company announced that ORR and PFS data from the 25 patient EGFRmut NSCL cohort is expected in Q3 2024 as well as data from the 40 patient EGFRwt cohort is expected in Q4 2024.
    • 04 Jun 2024 Preliminary results (as of January 2024, n=17 patients ) from the EGFR-WT NSCLC expansion cohort presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 01 Jun 2024 According to Affimed Therapeutics media release, company announced longer follow-up data from the EGFRwt cohort and initial clinical efficacy data from the EGFRmut cohort from the on-going AFM24-102 study in NSCLC.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top